Mark Nespeca
Neurology with Special Qualifications in Child Neurology · San Diego, CANPI 1942371703
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 170 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,608 and has fallen 93.9% since, to $158 in 2025.
Across 170 payments — averaging $25.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$892
- Livanova USA, Inc.$625
- Greenwich Biosciences, Inc.$457
- Jazz Pharmaceuticals Inc.$425
- Mallinckrodt Enterprises LLC$400
- Neurelis, Inc.$351
- plus $1K from 15 others
Across 1 payment — averaging $41,076 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Zogenix Inc.$41K
What the payments were for
- Food & beverage$4,270100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 55 | $892 |
| Livanova USA, Inc. | 23 | $625 |
| Greenwich Biosciences, Inc. | 12 | $457 |
| Jazz Pharmaceuticals Inc. | 7 | $425 |
| Mallinckrodt Enterprises LLC | 13 | $400 |
| Neurelis, Inc. | 7 | $351 |
| UCB, Inc. | 6 | $236 |
| Supernus Pharmaceuticals, Inc. | 9 | $180 |
| Biomarin Pharmaceutical Inc. | 3 | $152 |
| Aquestive Therapeutics, Inc. | 4 | $84 |
| Eisai Inc. | 5 | $79 |
| Upsher-smith Laboratories LLC | 3 | $72 |
| CSL Behring | 4 | $63 |
| Travere Therapeutics, Inc. | 8 | $53 |
| Novartis | 3 | $52 |
| Mallinckrodt Hospital Products Inc. | 2 | $50 |
| Neuropace, Inc. | 2 | $36 |
| Zogenix Inc. | 1 | $22 |
| Catalyst Pharmaceuticals, Inc. | 1 | $22 |
| Immedica Pharma US, Inc. | 1 | $22 |
| Biocodex, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,289 in reported general payments places this provider in the 70th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Other neurology with special qualifications in child neurology in San Diego
- Brittany PassiakSan Diego$90K
- Joseph GleesonSan Diego$69K
- John CrawfordSan Diego$27K
- Richard HaasSan Diego$27K
- Shifteh SattarSan Diego$21K
- Jennifer YangSan Diego$15K
- Doris TraunerSan Diego$15K
- Olivia Kim McManusSan Diego$11K
- Katherine LongardnerSan Diego$11K
- Aliya FrederickSan Diego$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.